Olympus (STU:OLY1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OLY1 Olympus Corp STU:OLY1
79 GF Score
Price €9.58
GF Value €14.06
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Olympus Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:OLY1
79GF Score
Olympus Corp STU:OLY1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Olympus (STU:OLY1) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of €9.58 is trading 31.9% below its estimated GF Value™ of €14.06. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for STU:OLY1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €14.06 vs. price of €9.58 (31.9% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the STU:OLY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Olympus Business Description

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
79GF Score

Get the complete analysis for STU:OLY1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.58
Price
€14.06
GF Value